Impact prediction of translocation of the mitochondrial outer membrane 70 as biomarker in Alzheimer's disease.
Impact prediction of translocation of the mitochondrial outer membrane 70 as biomarker in Alzheimer's disease.
复制标题
线粒体外膜易位作为阿尔茨海默病生物标志物的影响预测 70
DOI：
10.3389/fnagi.2022.1013943
复制
发表时间：
2022
影响因子：
4.8
通讯作者：
中科院分区：
文献类型：
--
作者：
线粒体功能障碍在阿尔茨海默病（AD）的发病机制中起着关键作用。外膜易位酶（TOM）复合物控制线粒体前体蛋白的输入以在病理生理条件下维持线粒体功能。然而，其在AD发展中的作用仍不清楚。TOM 70是存在于TOM复合物中的重要易位酶。在目前的研究中，我们发现APP/PS1小鼠的外周血和海马中的TOM 70水平降低。此外，我们还检测了AD、路易体痴呆（DLB）和卒中后痴呆（PSD）患者的全血TOM 70 mRNA水平。本研究发现AD患者血中TOM 70 mRNA水平降低，且与临床分期相关。因此，我们认为TOM 70的表达可能是AD诊断和监测疾病进展的有希望的生物标志物。
Mitochondrial dysfunction plays a key role in the pathogenesis of Alzheimer's disease (AD). The translocase of the outer membrane (TOM) complex controls the input of mitochondrial precursor proteins to maintain mitochondrial function under pathophysiological conditions. However, its role in AD development remains unclear. TOM70 is an important translocase present in the TOM complex. In the current study, we found that TOM70 levels were reduced in the peripheral blood and hippocampus of the APP/PS1 mice. In addition, we examined the whole-blood mRNA levels of TOM70 in patients with AD, dementia with Lewy bodies (DLB), and post-stroke dementia (PSD). Our study revealed that the mRNA level of TOM70 was decreased in the blood samples of patients with AD, which was also correlated with the progression of clinical stages. Therefore, we proposed that the expression of TOM70 could be a promising biomarker for AD diagnosis and monitoring of disease progression.